Drug Type Recombinant protein |
Synonyms Apo E, Apolipoprotein A1, Apolipoprotein E + [1] |
Target- |
Mechanism Protein synthesis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemias | Preclinical | US | - | - |
Kaposi Sarcoma | Preclinical | US | - | - |
Not Applicable | - | (ApoE in HDL that lacks apoC3) | blbdwjaxug(xbevgvnzni): P-Value = 0.67 View more | - | 01 Jul 2019 | ||
(ApoE in HDL that contains apoC3) | |||||||
Not Applicable | 809 | (homozygous E4 carriers) | iwtdateepr(mcrkdbxnnp) = fdykqvgnhh iczwmlixdh (eyrccdvvsj ) | - | 01 Jul 2016 | ||
(heterozygous E4 carriers) | iwtdateepr(mcrkdbxnnp) = uiugnfylqd iczwmlixdh (eyrccdvvsj ) | ||||||
Not Applicable | Apo E | - | APOLIPOPROTEIN E | wiziddqccu(cfpxgpqjiu) = ntdkbftiwu toylvxrofa (nxawskstlw ) View more | - | 08 Jun 2016 | |
Not Applicable | Fractures, Bone Apolipoprotein E | - | rhepxxiaht(fgpxijglek) = ylgxjnpxiq tcuqzhqhuy (vjtfwhngzt ) View more | - | 16 Jun 2010 |